The common thread in these 5 names is the bullish divergence between the lower lows in price and the higher low in the momentum study.
Drug companies are just too big a target to ignore.
Charts, secular woes show that benchmark IBB is under the weather.
These stocks should all show solid third-quarter results.
A broadening pattern shows potential for a continuation of an uptrend.
The stock shows bullish momentum and could climb 5%.
The company's stock will likely be among the first to turn.
Pernix looks poised for a strong 2016.
Momentum readings are improving.
We're watching the SPDR S&P Biotech ETF for clues to a rally. Rejected lows in the charts have been encouraging.


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.